DOCSLIB.ORG

2012 Annual Report (Essentials)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2012 Annual Report (Essentials) Please visit jdrf.org/2012annualreport to view the entire Annual Report online. 2012 Annual Report (Essentials) 42 YEARS. 42 REASONS. Please visit jdrf.org/2012annualreport to view the entire Annual Report online. Table of Contents CEO Message ...........................................................3 JDRF Supporters ....................................................5 Financials ................................................................24 Leadership ..............................................................25 About JDRF JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Type 1 diabetes is an autoimmune disease that strikes both children and adults. Unrelated to diet or lifestyle, T1D causes lifelong dependence on injected or pumped insulin and carries the constant danger of life-threatening complications. It requires intensive, 24/7 management. There are no days off, and there is no cure. Parents founded JDRF in 1970 to help their children with T1D by funding research to find a cure for this poorly understood and often deadly disease. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF has grown to become the largest nongovernmental funder of T1D research. JDRF has awarded more than $1.7 billion to diabetes research since our founding. Our goal is simple: we want to create a world without T1D. JDRF is the only global organization with a strategic plan to bring a continuous stream of life-changing therapies, and ultimately, a cure for T1D. 2 Please visit jdrf.org/2012annualreport to view the entire Annual Report online. CEO Message A Vision for the Future Our 2012 Annual Report is a JDRF isn’t just imagining keeping patients healthy celebration of JDRF’s 42nd this future. We’re making it and safe until our vision is year highlighting many of happen. JDRF is the only achieved. the amazing supporters and global organization with initiatives that make us the a strategic plan to bring We’re delivering a sustained global leader in T1D funding a continuous flow of life- stream of new, life-changing we are today. The progress changing therapies and, therapies. Underlying we have made in 42 years is ultimately, a cure for T1D. JDRF’s strategy is our work tremendous and our vision Our past investments have to optimize funding across for the future has never been yielded significant advances. the translational research clearer or stronger: a world without T1D. “I believe that one day in the future, In this world: we will declare victory and eliminate • Children with T1D and type 1 diabetes entirely—and JDRF their parents sleep through the night without will have led the way.” fear They have also taught us that continuum—from early • An intelligent pump there will likely be no single stage development through eliminates dangerous “eureka” moment that will delivery to patients. The high and low blood-sugar cause T1D to vanish all at most strategic allocation levels once. Instead, we know that of resources should create • A single daily insulin progress towards a cure will improvements that will injection maintains tight be a series of breakthroughs deliver relatively near-term control with no carb across different therapeutic meaningful clinical impact, counting approaches occurring on as well as ensure there is different timelines. JDRF’s active academic and industry • Developing T1D is no strategic plan for research engagement in early stages longer a concern for you funding will ensure there is an of the pipeline necessary or your loved ones ongoing stream of programs to support subsequent • There is no carb counting, underway to develop and generations of therapeutic no injections, no testing... commercialize therapies that interventions. no T1D lessen the impact of T1D— 3 Please visit jdrf.org/2012annualreport to view the entire Annual Report online. By driving investment across • The body’s ability to what we need is significant. the pipeline, we envision a regenerate islets to We’re doing all we can to cascade of progress that will restore normal glucose bridge that gap, but we need occur over the next 20 years. control while preventing your help. Your continued While we cannot predict the re-attack of the support will help change the exactly what the future holds, immune system; pace of T1D advancements, given the JDRF-funded accelerating progress down • Secondary prevention research underway today this the path to improving lives therapies that slow or progress is likely to include: and curing T1D. halt the progression • Progressive elimination of T1D before insulin Please join us in creating this of blood-glucose testing dependence; and future by giving to JDRF and automation of insulin • Primary prevention today. T1D doesn’t wait—and delivery through a series through universal neither can JDRF. of artificial pancreas childhood immunization. systems currently in Thank you for all that you do clinical trials; We’re uniquely positioned to for JDRF. • Ability to identify create a future without T1D. those most at risk for developing complications Driving this ambitious of T1D; research progress will require substantial annual • An implantable, islet cell investments to reach our Jeffrey Brewer replacement therapy goal of living in a time when that can restore insulin President and Chief Executive T1D is spoken about in the independence and Officer past tense. We know the eliminate the need for path forward is expensive immune suppression; and will take more than the • Glucose responsive $530 million JDRF has at insulin that supports a work around the globe today single shot of insulin per advancing our goals. The gap day or week; between what we have and 4 Please visit jdrf.org/2012annualreport to view the entire Annual Report online. FISCAL YEAR 2012 JDRF Supporters JDRF is the global leader in funding T1D research because of the continued support of our devoted donors. Every dollar we spend on research comes from you. Thank you for helping JDRF to bring life- changing therapies and, one day, a cure for T1D. JDRF Walk to Cure Diabetes ........................................6 Gala .........................................................................................7 Corporate Partners ...........................................................8 Major Donors and Partners ............................................9 BETA Society Members ................................................. 21 Stem Cell Research Fund ............................................ 22 5 Please visit jdrf.org/2012annualreport to view the entire Annual Report online. FISCAL YEAR 2012 JDRF Walk to Cure Diabetes The JDRF Walk to Cure Diabetes Program thanks all of our passionate and dedicated families, volunteers, local businesses, and corporations. Your support of the Walk is essential to JDRF’s fundraising strength and global growth. We also express our deepest gratitude to our many corporate partners for their commitment and support of the JDRF Walk to Cure Diabetes, both nationally and internationally. We extend a special thank-you to our national Walk partners: Advance Auto Parts, Ford Motor Company, Marshalls, Hy-Vee, Inc., Roche, and Walgreens. Congratulations to the FY2012 family Walk teams that raised $75,000 or more! Cohn Sisters: Mackenzie’s MM and Schuyler’s Cute Cupcakes Sydney’s SuperStars New York Chapter Eastern PA/Delaware Chapter Punkin’s Peeps Tessa’s Troopers New York Chapter Los Angeles Chapter Mimi’s Marchers Michael’s Legal Eagles/Kiwanis Long Island Chapter New York Chapter Harmelin Family Team Charlie’s Angels Eastern PA/Delaware Chapter Los Angeles Chapter 6 Please visit jdrf.org/2012annualreport to view the entire Annual Report online. FISCAL YEAR 2012 Gala We are pleased to recognize below the Honorees who helped lead their chapters in raising more than $100,000 through the 2012 Gala Program. Thank you to all the guests, supporters, and volunteers who make each JDRF Gala so successful and inspirational. Patrick and Shauna McFeeley Leanne DeShong Barrick Gold North America and Greater Western Carolinas Chapter Shook, Hardy & Bacon LLP Newmont Mining Corporation Kansas City Chapter Northern Nevada Branch Jerzy Gruhn Novo Nordisk David and Wendy Novak Linda Tharby Eastern PA/Delaware Chapter Yum! Brands, Inc. BD Medical Kentucky Chapter The Byrne Family John J. McDonough Northern NJ–Rockland County Florida Suncoast Chapter Shelby Notkin, Michelle Notkin Chapter Rosen, and Zach Rosen Dr. Bruce Bode Dr. Kevin Kaiserman The Terry Gallagher Family Georgia Chapter Linda Wallem, Stephen Wallem, and Rocky Mountain Chapter Showtime’s Nurse Jackie Genentech, Inc. Los Angeles Chapter Dr. Mitchell Eisenberg Greater Bay Area Chapter Sheridan Healthcare Ron Shapiro South Florida Chapter Anheuser-Busch Companies Shapiro Negotiations Institute Greater Missouri & Southern Illinois Maryland Chapter The Braswell Family Chapter Triangle/Eastern North Carolina Wade and Susan Kotula Chapter Mr. and Mrs. Stephen P. Sparkman II Northern Tool + Equipment Casey Auto Group MinnDakotas Chapter Arlo and Barbara DeKraai Hampton Roads Chapter Hille Foundation Bill Hornbuckle Gary and Anita Rathburn John J. McDonough MGM Resorts International Oklahoma/Northwest Arkansas Illinois Chapter Nevada Chapter Chapter—Tulsa Green Country Branch Michael Alter, Karen Case, Marci Leslie and Michael Weintraub Eisenstein and John Treece, and New England Chapter—Bay State Highmark Inc. Glen Tullman Branch Western Pennsylvania Chapter Illinois Chapter Liam McGee
Load more

Recommended publications
  • Download Authority Monitoring Report Volume 2 2013
    Medway Monitoring Report 2013 Volume 2 - Tables December 2013 Medway Monitoring Report 2013 Volume 2 - Tables Contents 1) Employment Land Availability Tables and Data 1 Employment graphs 2 Previously developed land 4 Floorspace supply 4 Section 1: Development completed by 31 March 2013 5 Section 2: B1 - B8 planning consents not started at 31 March 2013 7 Section 3: B1 - B8 development under construction at 31 March 2013 10 Section 4: Planning consents which have resulted in a B1 - B8 floorspace loss due to reconstruction/redevelopment during the year to 31 March 2013 12 Section 5: Potential loss of B1 - B8 floorspace in planning consents not started at 31 March 2013 14 Section 6: B1 - B8 planning consents expired without development at 31 March 2013 17 Section 7: B1 - B8 planning consents excluded at 31 March 2013 20 Section 8: B1 - B8 summary statistics; Planning consents valid 1 April 2012 to 31 March 2013 26 Section 9 – Employment pipeline sites (B1 – B8) 27 Section 10: Industrial Estates and Business Parks 29 2) Retail Land Availability Tables and Data 32 Retail net completions 33 Section 1: Development completed by 31 March 2013 34 Section 2: A1 - A5 planning consents not started at 31 March 2013 36 Section 3: A1 - A5 development under construction at 31 March 2013 40 Section 4: Planning consents which have resulted in an A1 - A5 floorspace loss due to reconstruction/redevelopment during the year to 31 March 2013 42 Section 5: Potential loss of A1 - A5 floorspace in planning consents not started at 31 March 2013 45 Section 6: A1
    [Show full text]
  • Diabetes Close up December Supplement, 2005, No. 53 J&J To
    Diabetes Close Up December supplement, 2005, No. 53 J&J To Buy Animas in Sublime Strategic Play T h e S h o r t e r V e r s i o n From the Editor: J&J’s LifeScan announced December 16 that it intends to buy Animas Corporation for $518 million in cash, or $24.50/share, a 35% premium over Animas’ closing price the 15th. We think this acquisition makes very good strategic sense – essentially, it’s the #1 glucose monitoring company buying the #2 pump player. In many respects, this was a classic J&J deal – Animas is newly profitable this year, the deal is immediately accretive, and it offers J&J an excellent leg up as it enters the pump market. Too, J&J had owned ~10% of Animas for some time. Now, while Animas is #2, it is still far behind leader Medtronic MiniMed, whose new(ish) leader, successful cardiac surgery veteran Bob Guezuraga has really impressed the diabetes community. Smart, ambitious, and seemingly hyper-focused, he appears very serious about taking the business to the next level and leaving success in diabetes as his legacy. What could be better for patients than significant focus industry-wide on better physiologic delivery? As competition heightens, we expect innovation to move faster – all good, from a patient perspective. Details on the acquisition are below – what J&J gets, what Animas gets, and what’s next. What a way to end what’s been a very dynamic year in diabetes … --Kelly L. Close DCU #53, December supplement 2005, J&J Buys Animas in Sublimely Strategic Deal.
    [Show full text]
  • Healthy People. Better World. Since 1948. Cover Photo: Jodie Willard Acenese Girl in a Relief Camp in Banda Aceh, Indonesia Photo: Jodie Willard
    direct relief international | annual report 2005 healthy people. better world. since 1948. cover photo: Jodie Willard www.Jodiewillard.com Acenese girl in a relief camp in Banda Aceh, Indonesia photo: Jodie Willard Dr. Vinya Ariyaratne and Direct Relief VP of Programs Chris Brady at Sarvodaya in Colombo, Sri Lanka This report is dedicated to Dr. Vinya Ariyaratne and Sarvodaya, the dynamic Sri Lankan community organization that he leads: for extraordinary, sustained leadership in thousands of Sri Lanka’s village communities, for joining altruistic ideals with productive initiatives, and for the enormous efforts undertaken in the aftermath of the Asian tsunami to help people rebuild their communities and lives. 1 | LETTER FROM THE PRESIDENT AND CEO | It is a privilege to report on Direct Relief’s 57th year of operations, in which our organization received more support and was able to provide more help to more people than in any previous year. This is the first report on our new fiscal year reporting period, which began on April 1, 2004, and ended on March 31, 2005. The year was marked by the extraordinary single-event tragedy of the Asian tsunami, which killed and displaced hundreds of thousands of people, and the slow-motion and less visible human tragedies that occur every day in developing countries. These events called upon our organization to focus more intensely than ever to help people facing tremendous challenges to meet basic health needs. Our longstanding focus on efficiency is rooted in the simple desire to help as many people as possible with whatever resources are entrusted to us.
    [Show full text]
  • On the Sustainable Development Goals and the Role of Islamic Finance
    WPS7266 Policy Research Working Paper 7266 Public Disclosure Authorized On the Sustainable Development Goals and the Role of Islamic Finance Public Disclosure Authorized Habib Ahmed Mahmoud Mohieldin with Jos Verbeek Farida Aboulmagd Public Disclosure Authorized Public Disclosure Authorized Office of the President’s Special Envoy on Post 2015 May 2015 Policy Research Working Paper 7266 Abstract The Sustainable Development Goals, the global development mobilized if the world is to succeed in meeting its targets. agenda for 2015 through 2030, will require unprecedented Thus, the potential for Islamic finance to play a role in sup- mobilization of resources to support their implementation. porting the Sustainable Development Goals is explored in Their predecessor, the Millennium Development Goals, this paper. Given the principles of Islamic finance that sup- focused on a limited number of concrete, global human port socially inclusive and development promoting activities, development targets that can be monitored by statistically the Islamic financial sector has the potential to contribute robust indicators. The Millennium Development Goals to the achievement of the Sustainable Development Goals. set the stage for global support of ambitious development The paper examines the role of Islamic financial institutions, goals behind which the world must rally. The Sustainable capital markets, and the social sector in promoting strong Development Goals bring forward the unfinished business growth, enhanced financial inclusion, and intermediation, of the Millennium Development Goals and go even further. reducing risks and vulnerability of the poor and more Because of the transformative and sustainable nature of the broadly contributing to financial stability and development. new development agenda, all possible resources must be This paper is a product of the Office of the President’s Special Envoy on Post 2015.
    [Show full text]
  • Annual Report 2019-2020
    Annual Report 2019-2020 Our Vision At North Kent Mind our vision is of a society where people experiencing mental health issues get the help they need when they need it, and can live fulfilling lives free from stigma. Our mission is to provide quality mental health services which empower people, which support their recovery and build their resilience. We provide direct services including supported housing, a wide range of community wellbeing and employment services (in groups or individually), low-cost counselling and other fee-paying services, and talking therapies on the NHS. We also campaign in response to local and national concerns, provide mental health education, and develop our work in response to changing needs. As part of the Mind network we have the following values: Open: We reach out to anyone who needs us Together: We’re stronger in partnerships Responsive: We listen, we act Independent: We speak out fearlessly Unstoppable: We never give up. Contents Our Vision 2 Contents 2 Board of Trustees 3-4 Chief Executives Report 5-6 Wellbeing Support Services 7-8 Employment Support Services 9 –10 Talking Therapies 11-12 Training 12 Housing Support Services 13-14 Central Services 15 Time to Change Champions 16 Peer Support Services 17 Fee Paying Services 18 Volunteering 19 Treasurer’s Report 20-21 The Team 22-23 2 Board of Trustees I am pretty skilled at stating the really obvious, or so I have been told by many people. So, holding true to form, 2020 has not been the year any of us expected. To be completely frank, I am not sure any of us could have predicted the Coronavirus pandemic.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • Open PDF File, 175.47 KB, for Top 100 Covered Recipients, Non Hospital
    Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events QUADRANT HEALTH BEVERLY MA Clinical 22D2063293 357395 Novartis CC0243 Other 61 $2,251,831.00 STRATEGIES INC Laboratory Pharmaceuticals 1 Total for Covered Recipient : QUADRANT HEALTH STRATEGIES INC $2,251,831.00 BOSTON BOSTON MA Clinical 22D0996308 241308 Celgene CC0109 Grants/ 2 $30,000.00 UNIVERSITY Laboratory Corporation Educational SCHOOL OF Gifts MEDICINE Csl Behring Llc CC0101 Education/ 2 $5,000.00 Training Depuy CC0135 CMEs, third- 2 $26,000.00 Orthopaedics, Inc., party Conferences, or Meetings Other 1 $7,500.00 Dr. Reddy's CC0592 Grants/ 2 $121,820.00 Laboratories, Inc Educational Gifts Janssen Biotech, CC0194 Grants/ 2 $105,000.00 Inc. Educational Gifts Other 1 $1,500.00 Janssen CC0535 CMEs, third- 2 $175,000.00 Pharmaceuticals, party Inc. Conferences, or Meetings Novo Nordisk Inc. CC0006 Grants/ 2 $136,436.00 Educational Gifts Smith & Nephew, CC0402 CMEs, third- 1 $1,000.00 Inc. party Conferences, or Meetings Stryker Corporation CC0290 CMEs, third- 1 $1,000.00 party Conferences, or Meetings Takeda CC0300 CMEs, third- 2 $60,218.00 Pharmaceuticals party Aug 1, 2016 1 8:44:29 AM Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events BOSTON BOSTON MA Clinical 22D0996308 241308 America, Inc CC0300 Conferences, or UNIVERSITY Laboratory Meetings SCHOOL OF Grants/ 3 $800,000.00 MEDICINE Educational Gifts Valeant CC0346 CMEs, third- 2 $5,000.00 Pharmaceuticals party North America Conferences, or Meetings W.L.
    [Show full text]
  • Effective Altruism and Extreme Poverty
    A Thesis Submitted for the Degree of PhD at the University of Warwick Permanent WRAP URL: http://wrap.warwick.ac.uk/152659 Copyright and reuse: This thesis is made available online and is protected by original copyright. Please scroll down to view the document itself. Please refer to the repository record for this item for information to help you to cite it. Our policy information is available from the repository home page. For more information, please contact the WRAP Team at: [email protected] warwick.ac.uk/lib-publications Effective Altruism and Extreme Poverty by Fırat Akova A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Philosophy Department of Philosophy University of Warwick September 2020 Table of Contents Acknowledgments vi Declaration viii Abstract ix Introduction 1 What is effective altruism? 1 What are the premises of effective altruism? 4 The aims of this thesis and effective altruism as a field of philosophical study 11 Chapter 1 13 The Badness of Extreme Poverty and Hedonistic Utilitarianism 1.1 Introduction 13 1.2 Suffering caused by extreme poverty 15 1.3 The repugnant conclusions of hedonistic utilitarianism 17 1.3.1 Hedonistic utilitarianism can morally justify extreme poverty if it is without suffering 19 1.3.2 Hedonistic utilitarianism can morally justify the secret killing of the extremely poor 22 1.4 Agency and dignity: morally significant reasons other than suffering 29 1.5 Conclusion 35 ii Chapter 2 37 The Moral Obligation to Alleviate Extreme Poverty 2.1 Introduction
    [Show full text]
  • Medtronics / Animas
    Completed acquisition by Medtronic plc of certain assets of Animas Corporation Decision on relevant merger situation and substantial lessening of competition Please note that [] indicates figures or text which have been deleted or replaced in ranges at the request of the parties for reasons of commercial confidentiality. SUMMARY 1. On 19 December 2017 Medtronic plc (Medtronic) acquired certain assets (the Target Assets) from Animas Corporation (Animas), a subsidiary of Johnson & Johnson (J&J) (the Merger). Medtronic and the Target Assets are together referred to as the Parties. 2. The Competition and Markets Authority (CMA) notes that the Merger does not involve an extensive transfer of assets. For example, it does not provide for the transfer of any physical assets (eg insulin pumps or consumables), fixed assets (eg manufacturing facilities), intellectual property, R&D assets and information, or employees. 3. The CMA notes, however, that the customer and patient records being transferred through the Merger appear to be of significant value and that the combination of these assets with the other transferred assets appears to support a degree of ‘economic continuity’ that may enable Medtronic to carry on the business previously supported by these assets. 4. The CMA therefore believes that the Target Assets may be an enterprise, and that as a result of the Merger, the enterprises of Medtronic and the Target Assets have ceased to be distinct. 5. The share of supply test is met. The four-month period for a decision, as extended, has not yet expired. The CMA therefore believes that it is or may be the case that a relevant merger situation has been created.
    [Show full text]
  • 2016 Annual Report
    ANNUAL REPORT 2016 MARCH 2017 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer I’ve worked in the health care industry for Rather, true innovations are the result of WE ARE UNITED nearly 30 years. It’s been both an honor and collaboration. And that collaboration is AND INSPIRED a privilege to work for Johnson & Johnson, driven by a diversity of ideas, individuals BY OUR CREDO, a company that touches the lives of over and disciplines – working together toward WHICH RINGS a billion people every day, around the a common goal. AS TRUE TODAY world. As I look at today’s health care AS IT DID WHEN landscape, it’s incredibly clear that the Today, more than ever, the world needs IT WAS WRITTEN pace of change has never been greater, leaders who are committed to working MORE THAN 70 or frankly, more exciting. together to help bring improved health YEARS AGO. and wellness to every person in every Today’s rapid change brings both corner of the globe. As the world’s largest opportunities and risks for any company and most broadly based health care in health care, and we are prepared company, we are uniquely positioned to help to address both. There are significant transform global health care; to shine a light challenges to overcome, but the tools, the on the most important issues we are facing; insights, the technologies, the innovations to collaborate across boundaries and – both evolutions and revolutions – all borders; to uncover scientific insights and combine to make today one of the most ideas; and to dedicate resources towards promising times for human health and for creating tomorrow’s breakthroughs.
    [Show full text]
  • Foxe's Book of Martyrs
    FOXE'S BOOK OF MARTYRS CHAPTER I - History of Christian Martyrs to the First General Persecutions Under Nero Christ our Savior, in the Gospel of St. Matthew, hearing the confession of Simon Peter, who, first of all other, openly acknowledged Him to be the Son of God, and perceiving the secret hand of His Father therein, called him (alluding to his name) a rock, upon which rock He would build His Church so strong that the gates of hell should not prevail against it. In which words three things are to be noted: First, that Christ will have a Church in this world. Secondly, that the same Church should mightily be impugned, not only by the world, but also by the uttermost strength and powers of all hell. And, thirdly, that the same Church, notwithstanding the uttermost of the devil and all his malice, should continue. Which prophecy of Christ we see wonderfully to be verified, insomuch that the whole course of the Church to this day may seem nothing else but a verifying of the said prophecy. First, that Christ hath set up a Church, needeth no declaration. Secondly, what force of princes, kings, monarchs, governors, and rulers of this world, with their subjects, publicly and privately, with all their strength and cunning, have bent themselves against this Church! And, thirdly, how the said Church, all this notwithstanding, hath yet endured and holden its own! What storms and tempests it hath overpast, wondrous it is to behold: for the more evident declaration whereof, I have addressed this present history, to the end, first, that the wonderful works of God in His Church might appear to His glory; also that, the continuance and proceedings of the Church, from time to time, being set forth, more knowledge and experience may redound thereby, to the profit of the reader and edification of Christian faith.
    [Show full text]
  • The Dover Road
    THE DOVER ROAD BY CHARLES G. HARPER The Dover Road I Of all the historic highways of England, the story of the old Road to Dover is the most difficult to tell. No other road in all Christendom (or Pagandom either, for that matter) has so long and continuous a history, nor one so crowded in every age with incident and associations. The writer, therefore, who has the telling of that story to accomplish is weighted with a heavy sense of responsibility, and though (like a village boy marching fearfully through a midnight churchyard) he whistles to keep his courage warm, yet, for all his outward show of indifference, he keeps an awed glance upon the shadows that beset his path, and is prepared to take to his heels at any moment. And see what portentous shadows crowd the long reaches of the Dover Road, and demand attention! Cæsar’s presence haunts the weird plateau of Barham Downs, and the alert imagination hears the tramp of the legionaries along Watling Street on moonlit nights. Shades of Britons, Saxons, Danes, and Normans people the streets of the old towns through which the highway takes its course, or crowd in warlike array upon the hillsides. Kings and queens, nobles, saints of different degrees of sanctity, great blackguards of every degree of blackguardism, and ecclesiastics holy, haughty, proud, or pitiful, rise up before one and terrify with thoughts of the space the record of their doings would occupy; in fine, the wraiths and phantoms of nigh upon two thousand years combine to intimidate the historian.
    [Show full text]